HuMab 5B1 targeted amanitin conjugate - MabVax/Wilex

Drug Profile

HuMab 5B1 targeted amanitin conjugate - MabVax/Wilex

Alternative Names: HuMab 5B1-ADC; HuMab 5B1-ATAC

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Heidelberg Pharma; MabVax Therapeutics
  • Developer Heidelberg Pharma Research; MabVax Therapeutics
  • Class Immunoconjugates; Immunotoxins
  • Mechanism of Action RNA polymerase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pancreatic cancer

Most Recent Events

  • 09 Oct 2017 Heidelberg Pharma is now called Heidelberg Pharma Research
  • 06 Jan 2017 Preclinical trials in Pancreatic cancer in Germany (Parenteral) before January 2017
  • 06 Jan 2017 Preclinical trials in Pancreatic cancer in USA (Parenteral) before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top